Polymorphisms at 3q26.2 and 3q26.3, involving MECOM and the intergenic region between HBS1L and MYB, have been associated to increased MPN risk in three out of the four above referenced studies [11,12,13]; the association did not emerge in the Icelandic population, described by Oddsson et al. [10]. Here, MYB is linked to myeloproliferative neoplasm.